1) All paper authors should be directly involved in planning, conducting, and arranging the study, and collecting and analyzing data and reading the manuscript, and should agree with the submittal of the paper.
2) Throughout the whole process, the corresponding author cannot be changed. To change the order of, adding or deleting author (s) during the examination period, the submission of an agreement including signatures of all authors is mandatory. Upon completion of all examinations and confirmation of publication, any change in author(s) is not allowed.
3) Same or similar paper once submitted to Hip & Pelvis should not be published in any other academic journals, and ownership of the paper published by Hip & Pelvis permanently belongs to Hip & Pelvis and accordingly, whole or part of the paper should not be published in any other journal without permission from the editor of Hip & Pelvis. Duplicated or redundant submission is allowed only in case of secondary publication fulfilling the requirements described in the preceding clauses, and authors should abide by the ethics regulation on publication described in the preceding clauses.
4) In case that the study submitted to Hip & Pelvis is targeting human beings, the study should meet ethics standards of Declaration of Helsinki (2013) and approval from Institutional Review Board (IRB) should be obtained in principle. In the case of an animal experiment study, the whole study process should meet the regulations of the in-house ethics committee or NIH Guide for the Care and Use of Laboratory Animals and in principle and the approval from the animal use committee or inhouse committee should be obtained. When necessary, Hip & Pelvis panel of editors can require verification of patient agreements and a letter of approval released by the relevant ethics committee.
5) In case that the authors received support in part or whole of the materials used in the study, or that interests are involved in the production of the paper or thereafter, these situations should be described in the paper.
7) Hip & Pelvis will follow the guidelines by the Committee on Publication Ethics (COPE, http://publicationethics.org/) for settlement of any misconduct. In case of suspected misconduct such as fabrication, falsification or duplication, each ethical issue is followed by recommended actions as advised by COPE guidelines and flowcharts.
8) All reviewers have a responsibility to report to the Editor about any suspected issues with the manuscript. If the investigation proves scientific misconduct, publish a retraction of the article. If warranted, the authors should be invited to prepare the retraction, which should be submitted with an assignment of copyright statement that has been signed by all authors. If the paper has not been published then the Editor can always reject the paper. Instances of misconduct in the publication process will be shared with the editorial board of the Hip & Pelvis journal. The Editor may wish to impose sanctions, notify editors of other biomedical journals, and depending on the severity of the allegation, notify the author's institution. The Hip & Pelvis will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when the misconduct is founded.
① Registration of Clinical Trial Research
It is recommended that any research that deals with a clinical trial be registered with a primary national clinical trial registration site, such as http://cris.cdc.go.kr/, or other sites accredited by the WHO as listed at http://www.who.int/ictrp/en/.
② Conflict of Interest
The corresponding author of an article is asked to inform the editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A conflict of interest may exist when an author (or the author's institution or employer) has financial support from pharmaceutical or commercial companies or political pressures from interest groups or personal relationships that could influence (or bias) the author's decisions, work, or manuscript. A potential conflict of interest should be disclosed in the manuscript even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or private connections to pharmaceutical companies, political pressure from interest groups, or academic problems (e.g., employment/affiliation, grants or funding, consultancies, stockownership or options, royalties, or patents filed, received, or pending). If the study was sponsored by a third party, authors should describe the role of the study sponsor in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Where authors have no competing interests, the statement should read “No potential conflict of interest relevant to this article was reported.”
③ Statement of Informed Consent
Copies of written informed consent and institutional review board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. In addition, for studies conducted with human subjects, the method by which informed consent was obtained from the participants (i.e., verbal or written) also needs to be stated in the Methods section.
④ Patient Photographic and Videographic Consent
Patients introduced in the manuscripts should be informed and aware that their photographs, videotapes, and other images (imaging records) will be released by the authors, and the authors should attach the Authorization and Release Form available at the Hip & Pelvis website (https://submit.hipandpelvis.or.kr/submission/Login.html/ or https://hipandpelvis.or.kr/) including each patient's signature.
⑥ Copyright and Licensing
(1) Copyright policy: Upon publication of the articles, all the copyrights are transferred to the Korean Hip Society. Articles are accepted on the understanding that no substantial part other than the abstract has been or will be published elsewhere. A copyright transfer form should be submitted to the editorial office by faxing a copy to +82-2-440-7497, by regular mail, or by emailing the scanned copyright transfer form at the time of acceptance. It is identical to the Creative Commons Attribution Noncommercial License at http://creativecommons.org/licenses/by-nc/4.0/.
(2) Licensing information: This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by-nc/4.0/).
(3) Supporting Information: This journal was supported by the Korean Federation of Science and Technology Societies (KOFST) Grant funded by the Korean Government (MEST).
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. If the number of authors is greater than six, there should be a list of each author's role for the submitted paper.
After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors on the paper. Copyright assignment must be completed by every author.
⑧ Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. The duplication will be checked through crosscheck (https://app.ithenticate.com/) or eTBLAST (http://etest.vbi.vt.edu/etblast3/) before submission. If duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutes will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, illustrations, and tables.
⑨ Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
9) The editorial board will continuously work for monitoring /safeguarding research and publication ethics: Registration of Clinical Trial Research / Conflict of Interest / Statement of Informed Consent / Patient Photographic and Videographic Consent / Statement of Human and Animal Rights / Copyright and Licensing / Authorship / Plagiarism / Originality and Duplicate Publication / Secondary Publication. In case of unjustifiable act in the research and publication ethics, it shall decide whether to take disciplinary action or not after thorough investigation based on various standardized guidelines (COPE) by the editorial ethics committee. The decided contents shall be reported to the board of directors in the Korean Hip Society and the board of directors shall announce the fact after deciding the final consideration on the discipline disposition reported to the ethics committee.